Back to News
Market Impact: 0.2
IDEAYA And Servier Dose First Patient In Global Phase 3 OptimUM-11 Trial For Uveal Melanoma
Source: Nasdaq
Healthcare & Biotech
IDEAYA Biosciences and Servier announced that the first patient has been dosed in the OptimUM-11 study. The milestone advances the companies' precision-oncology clinical development program, though no efficacy, safety, financial, or trial-design data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
IDYA0.45
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine